262 related articles for article (PubMed ID: 29367644)
1. Intravitreal injection of aflibercept, an anti-VEGF antagonist, down-regulates plasma von Willebrand factor in patients with age-related macular degeneration.
Yamashita M; Matsumoto M; Hayakawa M; Sakai K; Fujimura Y; Ogata N
Sci Rep; 2018 Jan; 8(1):1491. PubMed ID: 29367644
[TBL] [Abstract][Full Text] [Related]
2. Short-term outcomes of switching anti-VEGF agents in eyes with treatment-resistant wet AMD.
Batioglu F; Demirel S; Özmert E; Abdullayev A; Bilici S
BMC Ophthalmol; 2015 Apr; 15():40. PubMed ID: 25885684
[TBL] [Abstract][Full Text] [Related]
3. Systemic counterregulatory response of placental growth factor levels to intravitreal aflibercept therapy.
Zehetner C; Bechrakis NE; Stattin M; Kirchmair R; Ulmer H; Kralinger MT; Kieselbach GF
Invest Ophthalmol Vis Sci; 2015 May; 56(5):3279-86. PubMed ID: 26024110
[TBL] [Abstract][Full Text] [Related]
4. Systemic levels of vascular endothelial growth factor before and after intravitreal injection of aflibercept or ranibizumab in patients with age-related macular degeneration: a randomised, prospective trial.
Zehetner C; Kralinger MT; Modi YS; Waltl I; Ulmer H; Kirchmair R; Bechrakis NE; Kieselbach GF
Acta Ophthalmol; 2015 Mar; 93(2):e154-9. PubMed ID: 25488124
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of intravitreal injection of aflibercept in neovascular age-related macular degeneration with or without choroidal vascular hyperpermeability.
Hata M; Oishi A; Tsujikawa A; Yamashiro K; Miyake M; Ooto S; Tamura H; Nakanishi H; Takahashi A; Yoshikawa M; Yoshimura N
Invest Ophthalmol Vis Sci; 2014 Nov; 55(12):7874-80. PubMed ID: 25395483
[TBL] [Abstract][Full Text] [Related]
6. Intravitreal aflibercept versus intravitreal ranibizumab in patients with age-related macular degeneration: a comparative effectiveness study.
Smit C; Wiertz-Arts K; van de Garde EM
J Comp Eff Res; 2018 Jun; 7(6):561-567. PubMed ID: 29855194
[TBL] [Abstract][Full Text] [Related]
7. Intraocular inflammatory cytokines in patients with neovascular age-related macular degeneration before and after initiation of intravitreal injection of anti-VEGF inhibitor.
Sato T; Takeuchi M; Karasawa Y; Enoki T; Ito M
Sci Rep; 2018 Jan; 8(1):1098. PubMed ID: 29348424
[TBL] [Abstract][Full Text] [Related]
8. Analysis focusing on plasma von Willebrand factor in pachychoroid neovasculopathy and age-related macular degeneration.
Hirai H; Yamashita M; Matsumoto M; Hayakawa M; Sakai K; Ueda T; Ogata N
Sci Rep; 2021 Oct; 11(1):19987. PubMed ID: 34620972
[TBL] [Abstract][Full Text] [Related]
9. Intravitreal bevacizumab and aflibercept for the treatment of exudative age-related macular degeneration.
Selid PD; Jundt MC; Fortney AC; Beal JR
Ophthalmic Surg Lasers Imaging Retina; 2014; 45(4):275-81. PubMed ID: 25037009
[TBL] [Abstract][Full Text] [Related]
10. Recovery of plasma vascular endothelial growth factor concentrations during aflibercept loading phase and after the transition to bimonthly treatment for neovascular age-related macular degeneration.
Roald AB; Aass HC; Moe MC
Br J Ophthalmol; 2015 Dec; 99(12):1610-3. PubMed ID: 25966740
[TBL] [Abstract][Full Text] [Related]
11. Aflibercept Treatment for Neovascular Age-related Macular Degeneration and Polypoidal Choroidal Vasculopathy Refractory to Anti-vascular Endothelial Growth Factor.
Moon DRC; Lee DK; Kim SH; You YS; Kwon OW
Korean J Ophthalmol; 2015 Aug; 29(4):226-32. PubMed ID: 26240506
[TBL] [Abstract][Full Text] [Related]
12. SYSTEMIC PHARMACOKINETICS AND PHARMACODYNAMICS OF INTRAVITREAL AFLIBERCEPT, BEVACIZUMAB, AND RANIBIZUMAB.
Avery RL; Castellarin AA; Steinle NC; Dhoot DS; Pieramici DJ; See R; Couvillion S; Nasir MA; Rabena MD; Maia M; Van Everen S; Le K; Hanley WD
Retina; 2017 Oct; 37(10):1847-1858. PubMed ID: 28106709
[TBL] [Abstract][Full Text] [Related]
13. Suppression of intraocular vascular endothelial growth factor during aflibercept treatment of age-related macular degeneration.
Fauser S; Schwabecker V; Muether PS
Am J Ophthalmol; 2014 Sep; 158(3):532-6. PubMed ID: 24879948
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of outer retinal tubulations in eyes switched from intravitreal ranibizumab to aflibercept for treatment of exudative age-related macular degeneration.
Massamba N; Dirani A; Butel N; Fardeau C; Bodaghi B; Ingram A; Lehoang P
Graefes Arch Clin Exp Ophthalmol; 2017 Jan; 255(1):61-67. PubMed ID: 27397583
[TBL] [Abstract][Full Text] [Related]
15. Arteriosclerotic Changes after Intravitreal Injections of Anti-Vascular Endothelial Growth Factor Drugs in Patients with Exudative Age-Related Macular Degeneration.
Shiba T; Takahashi M; Yoshida I; Taniguchi H; Matsumoto T; Hori Y
Ophthalmologica; 2016; 235(4):225-32. PubMed ID: 27082736
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of intravitreal aflibercept in Japanese patients with exudative age-related macular degeneration.
Saito M; Kano M; Itagaki K; Sekiryu T
Jpn J Ophthalmol; 2017 Jan; 61(1):74-83. PubMed ID: 27660164
[TBL] [Abstract][Full Text] [Related]
17. Vitreomacular Interface after Anti-Vascular Endothelial Growth Factor Injections in Neovascular Age-Related Macular Degeneration.
Veloso CE; Kanadani TM; Pereira FB; Nehemy MB
Ophthalmology; 2015 Aug; 122(8):1569-72. PubMed ID: 26038338
[TBL] [Abstract][Full Text] [Related]
18. CHANGES IN PLASMA VASCULAR ENDOTHELIAL GROWTH FACTOR LEVEL AFTER INTRAVITREAL INJECTION OF BEVACIZUMAB, AFLIBERCEPT, OR RANIBIZUMAB FOR DIABETIC MACULAR EDEMA.
Hirano T; Toriyama Y; Iesato Y; Imai A; Murata T
Retina; 2018 Sep; 38(9):1801-1808. PubMed ID: 29280940
[TBL] [Abstract][Full Text] [Related]
19. Intraocular pressure in patients with neovascular age-related macular degeneration switched to aflibercept injection after previous anti-vascular endothelial growth factor treatments.
Rusu IM; Deobhakta A; Yoon D; Lee M; Slakter JS; Klancnik JM; Thompson D; Freund KB
Retina; 2014 Nov; 34(11):2161-6. PubMed ID: 25072648
[TBL] [Abstract][Full Text] [Related]
20. Intravitreal anti-VEGF injections for treating wet age-related macular degeneration: a systematic review and meta-analysis.
Ba J; Peng RS; Xu D; Li YH; Shi H; Wang Q; Yu J
Drug Des Devel Ther; 2015; 9():5397-405. PubMed ID: 26451092
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
